Previous issue | Volume 94 | ESPE2021 | Next issue

59th Annual ESPE (ESPE 2021 Online)

22 Sep 2021 - 26 Sep 2021

Card image cap
The 59th ESPE Annual Meeting will now be held online in September 2021.

ePoster Category 1

Growth Hormone and IGFs B

hrp0094p1-171 | Growth Hormone and IGFs B | ESPE2021

Diagnosing growth hormone deficiency - Can a combined arginine and clonidine stimulation test replace two separate tests?

Oron Tal , Krieger Avihu , Yakobovich-Gavan Michal , Tenenbaum Ariel , Diamant Rotem , Phillip Moshe , Lazar Liora ,

Objective: Given a large number of false-positive growth hormone deficiency (GHD) diagnoses from a single GH stimulation test in normal children, two different pharmacological tests, performed on separate days or sequentially, are required. This study aims to assess the reliability and safety of a combined clonidine-arginine stimulation test (CACST).Design: Retrospective, single-center, observational study....

hrp0094p1-172 | Growth Hormone and IGFs B | ESPE2021

Glucagon Testing of Childhood-Onset Growth Hormone Deficiency during Transition

Guglielmi Davide , Napoli Flavia , Allegri Anna Elsa Maria , Patti Giuseppa , Fava Daniela , Crocco Marco , Maghnie Mohamad , Di Iorgi Natascia ,

Objectives: To reassess growth hormone (GH) status by the means of Insulin (ITT) and Glucagon tests (GL) in young adults with childhood-onset GHD.Methods: We present preliminary data of 67 subjects (25F, 42M) recruited from a single Center, in whom anthropometrics, ITT and GL stimulation tests and IGF-1 evaluations were undertaken at adult height achievement, at a mean age of 17.3±2.2 (range: 13.3-25.7). Subjects we...

hrp0094p1-173 | Growth Hormone and IGFs B | ESPE2021

Growth hormone receptor 6Ω pseudoexon activation: a novel cause of severe growth hormone insensitivity

Cottrell Emily , Maharaj Avinaash , Williams Jack , Chatterjee Sumana , Cirillo Grazia , Giudice Emanuele Miraglia del , Festa Adalgisa , Palumbo Stefania , Capalbo Donatella , Salerno Mariacarolina , Pignata Claudio , Savage Martin O. , Schilbach Katharina , Bidlingmaier Martin , Hwa Vivian , Metherell Louise A. , Grandone Anna , Storr Helen L. ,

Context: Severe forms of growth hormone insensitivity (GHI) are characterised by extreme short stature, dysmorphism and metabolic anomalies. They are classically caused by homozygous or compound heterozygous mutations of the growth hormone receptor gene (GHR). Genetic analysis traditionally focuses on the exonic regions of genes that encode proteins rather than the intervening non-coding sequences. These seldom explored non-coding regions may harbour ...

hrp0094p1-174 | Growth Hormone and IGFs B | ESPE2021

High incidence and male predominance of transient form of isolated growth hormone (GH) deficiency in children. What is the optimal time for GH therapy withdrawal and retesting?

Smyczyńska Joanna , Hilczer Maciej , Lewiński Andrzej , Smyczyńska Urszula , Stawerska Renata ,

Introduction: Normal growth hormone (GH) secretion after the attainment of final height (FH) is observed in the majority of GH-treated children with GH deficiency (GHD), however it is unclear when such normalization of GH secretion occurs.The Aim: Of the study was to assess the incidence of transient GHD in retesting with respect to pediatric criteria in the patients with isolated GHD diagnosed in childhood, depending on the moment of GH...

hrp0094p1-175 | Growth Hormone and IGFs B | ESPE2021

Growth without growth hormone. A tertiary care hospital’s experience

Cuenca-Carcelen Sandra , Tome-Masa Irene , Guemes Maria , Angel Martos-Moreno Gabriel , Pozo-Roman Jesus , Argente Jesus ,

Introduction: Growth without growth hormone (GWGH) is a rare phenomenon described in patients with hypothalamic structural pathology who present a normal growth rate in spite of growth hormone (GH) deficiency and low concentrations of insulin-like growth factor-1 (IGF-1). Possible aetiologies involve hyperinsulinaemia, hyperprolactinaemia or hyperleptinaemia; however, the exact mechanism is still unknown.Objective: We ai...

hrp0094p1-176 | Growth Hormone and IGFs B | ESPE2021

Irisin in the growth hormone deficient children: before and on rhGH therapy.

Seifert Monika , Noczynska Anna , Wikiera Beata ,

Introduction: In recent years, one of the most frequently studied focuses is the pathophysiology of adipose and muscle tissue; however, in the literature there is no report about regulatory proteins (myokines/adipomyokines), which expression affects the body’s metabolism and communication between tissues especially in children population. Irisin (Ir) is one of the adipomyokines, which induces the conversion of white adipocytes into beige adipose tissue, a...

hrp0094p1-177 | Growth Hormone and IGFs B | ESPE2021

Immunogenicity of recombinant growth hormone and relationship its growth-promoting effect in the children with short stature

Karaoglan Murat , Isbilen Elif , Keskin Mehmet ,

Background/Aim: Although there are many well-known components that affect the growth response to recombinate growth hormone (rGH), its effect on total height gain is still not fully predictable. Current knowledge on the relationship between growth response to rGH and its immunogenicity is limited. The aim of the study was to reveal its relationship with the antibody formation against rGH and growth-promoting effect.Materials and Methods:...

hrp0094p1-178 | Growth Hormone and IGFs B | ESPE2021

Study on linear growth of children with idiopathic short children (ISS) with Low Insulin-like growth factor 1 (IGFI) at diagnosis: Growth hormone (GH) treatment versus no treatment.

Elsiddig Sohair , Soliman Ashraf , khalil Ahmed , Alaaraj Nada , Ahmed Hannah ,

ISS is a condition in which the height of the individual is more than 2SD below the corresponding mean height for a given age, sex, and population, in whom no identifiable disorder is present. At presentation, some of these children have relatively low IGF-I levels which theoretically can affect their response to GH therapy. The question is: does GH treatment of these children improve their linear growth compared to no treatment?Aim: We ...

hrp0094p1-179 | Growth Hormone and IGFs B | ESPE2021

Novel dominant negative GH receptor variants provide important insights into GH receptor physiology

Andrews Afiya , Cottrell Emily , Maharaj Avinaash , Ladha Tasneem , Williams Jack , Metherell Louise A , McCormick Peter J , Storr Helen L ,

Background: Growth hormone insensitivity (GHI) encompasses normal/elevated growth hormone (GH), low IGF-I levels and growth restriction. Non-classical/mild-moderate GHI is an emerging entity which is poorly characterised, and, in many subjects, the underlying cause is unclear. Heterozygous dominant negative (DN) variants located in the intracellular/transmembrane domain of the GH receptor (GHR) cause a ‘non-classical’ GHI phenotype.<p class="abst...

hrp0094p1-180 | Growth Hormone and IGFs B | ESPE2021

The miRNA network and the interplay between growth and cancer regulating pathways in prepubertal patients with idiopathic isolated growth hormone deficiency (IGHD) on growth hormone (GH) treatment

Catellani Cecilia , Ravegnini Gloria , Sartori Chiara , Righi Beatrice , Poluzzi Silvia , Predieri Barbara , Iughetti Lorenzo , Angelini Sabrina , Elisabeth Street Maria ,

GH and IGF1 regulate cell proliferation, differentiation and apoptosis playing a key role in growth, and leading to consider potential oncogenic effects of GH. To evaluate possible oncogenic risks in GHD patients who underwent GH replacement therapy, the SAGhE consortium was created. The data collected have not yielded definite conclusions and continuous surveillance is yet required. MiRNAs are regulators of gene expression, and are involved in many biological processes. We ai...